NYSE:ALB - Albemarle Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$93.33 -0.33 (-0.35 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$93.33
Today's Range$92.20 - $93.62
52-Week Range$86.75 - $144.99
Volume1.70 million shs
Average Volume1.38 million shs
Market Capitalization$10.34 billion
P/E Ratio20.33
Dividend Yield1.44%
Beta1.63

About Albemarle (NYSE:ALB)

Albemarle logoAlbemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. Its Lithium and Advanced Materials segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties, as well as reagents, such as butyllithium and lithium aluminum hydride for applications in lithium batteries for consumer electronics and automobiles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets. It also offers cesium products for the chemical and pharmaceutical markets; zirconium, barium, and titanium products for various pyrotechnical applications; technical services, such as the handling and use of reactive lithium products; and recycling services for lithium-containing by-products. In addition, this segment offers performance catalyst solutions comprising organometallics, polymer catalysts, and curatives for polyolefin polymers, packaging, non-packaging, films, injection molding, alpha-olefins, polyurethanes, epoxies, and engineered resins markets. Its Bromine Specialties segment offers bromine and bromine-based solutions for fire safety, chemical synthesis, mercury control, water purification, beef and poultry processing, and other industrial applications, as well as oil and gas well drilling, and completion fluids applications; and tertiary amines, biocides, disinfectants, and sanitizers. Its Refining Solutions segment offers clean fuels technologies, which is primarily composed of hydroprocessing catalysts; and fluidized catalytic cracking catalysts and additives for refining industry. It serves energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, crop protection, and custom chemistry services markets. The company was founded in 1994 and is headquartered in Charlotte, North Carolina.

Receive ALB News and Ratings via Email

Sign-up to receive the latest news and ratings for ALB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Plastics materials & resins
Sub-IndustrySpecialty Chemicals
SectorBasic Materials
SymbolNYSE:ALB
CUSIP01265310
Webwww.albemarle.com
Phone980-299-5700

Debt

Debt-to-Equity Ratio0.36
Current Ratio2.48
Quick Ratio1.72

Price-To-Earnings

Trailing P/E Ratio20.33
Forward P/E Ratio17.78
P/E Growth1.09

Sales & Book Value

Annual Sales$3.07 billion
Price / Sales3.37
Cash Flow$6.4499 per share
Price / Cash14.47
Book Value$34.55 per share
Price / Book2.70

Profitability

EPS (Most Recent Fiscal Year)$4.59
Net Income$54.85 million
Net Margins4.27%
Return on Equity13.80%
Return on Assets7.19%

Miscellaneous

Employees5,400
Outstanding Shares110,760,000

Albemarle (NYSE:ALB) Frequently Asked Questions

What is Albemarle's stock symbol?

Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALB."

How often does Albemarle pay dividends? What is the dividend yield for Albemarle?

Albemarle announced a quarterly dividend on Tuesday, May 8th. Shareholders of record on Friday, June 15th will be given a dividend of $0.335 per share on Monday, July 2nd. This represents a $1.34 dividend on an annualized basis and a yield of 1.44%. The ex-dividend date is Thursday, June 14th. View Albemarle's Dividend History.

How were Albemarle's earnings last quarter?

Albemarle Co. (NYSE:ALB) issued its earnings results on Wednesday, May, 9th. The specialty chemicals company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.20 by $0.10. The specialty chemicals company earned $821.60 million during the quarter, compared to analyst estimates of $798.20 million. Albemarle had a net margin of 4.27% and a return on equity of 13.80%. Albemarle's quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.05 EPS. View Albemarle's Earnings History.

When is Albemarle's next earnings date?

Albemarle is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Albemarle.

What guidance has Albemarle issued on next quarter's earnings?

Albemarle issued an update on its FY18 earnings guidance on Wednesday, May, 9th. The company provided earnings per share guidance of $5.10-5.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.17. The company issued revenue guidance of $3.2-3.4 billion, compared to the consensus revenue estimate of $3.30 billion.

What price target have analysts set for ALB?

24 Wall Street analysts have issued 1 year price targets for Albemarle's stock. Their predictions range from $36.00 to $157.00. On average, they expect Albemarle's share price to reach $125.0243 in the next twelve months. View Analyst Ratings for Albemarle.

What are Wall Street analysts saying about Albemarle stock?

Here are some recent quotes from research analysts about Albemarle stock:
  • 1. According to Zacks Investment Research, "Albemarle remains focused on strengthening its lithium business. It is well placed to leverage strong growth in the battery-grade lithium market. The company is also likely to gain from the synergies of Rockwood Holdings acquisition. Further, Albemarle is divesting non-core assets to boost growth opportunities and focus on its key businesses. The company also remains committed to deliver incremental returns to shareholders. However, Albemarle is facing headwinds associated with higher expected tax rate in 2018 and challenges in bromine and catalysts units. Moreover, a significant rise in capital spending is expected to hurt its free cash flows this year. The company has also underperformed the industry it belongs to over the past six months." (6/7/2018)
  • 2. KeyCorp analysts commented, "ITRI beat 4Q17 consensus on top/bottom line while guiding FY18 adj. EPS midpoint 2% below Street. Amid moving parts—Silver Spring (now “Networks”) integration, a new restructuring program, and ongoing impacts from 2016 restructuring—we have three primary takeaways. First, we think FY18 guidance embeds healthy organic growth at legacy Itron, supported by 12-month backlog up 22%. Second, we see revenue recog. timing at Networks as a potential dilutive factor in FY18 guidance (on top of Networks’ already higher cost structure) that understates margin expansion at legacy Itron. Third, we believe the restructuring plan is mainly a continuation of existing optimization programs and supports our view of the long-term adj. EBITDA trajectory (which moves slightly lower along with our PT to $77). Maintain Outperform." (3/1/2018)

Who are some of Albemarle's key competitors?

Who are Albemarle's key executives?

Albemarle's management team includes the folowing people:
  • Mr. Luther C. Kissam IV, Chairman, Pres & CEO (Age 53)
  • Mr. Scott A. Tozier, Exec. VP & CFO (Age 52)
  • Mr. Donald J. LaBauve Jr., Chief Accounting Officer, VP & Corp. Controller (Age 51)
  • Ms. Karen G. Narwold, Chief Admin. Officer, Exec. VP, Gen. Counsel & Corp. Sec. (Age 58)
  • Dr. Ronald C. Zumstein, Sr. VP of Operational Excellence (Age 56)

Has Albemarle been receiving favorable news coverage?

Media stories about ALB stock have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Albemarle earned a coverage optimism score of 0.10 on Accern's scale. They also assigned news stories about the specialty chemicals company an impact score of 46.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Albemarle's major shareholders?

Albemarle's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (8.17%), BlackRock Inc. (7.65%), Iridian Asset Management LLC CT (1.79%), Global X Management Co. LLC (1.47%), Artisan Partners Limited Partnership (1.41%) and Northern Trust Corp (1.11%). Company insiders that own Albemarle stock include Douglas L Maine, John Sherman Jr, Karen G Narwold, Luther C Iv Kissam, Matthew Juneau and Scott Tozier. View Institutional Ownership Trends for Albemarle.

Which major investors are selling Albemarle stock?

ALB stock was sold by a variety of institutional investors in the last quarter, including AGF Investments Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Lord Abbett & CO. LLC, OppenheimerFunds Inc., Sei Investments Co., Handelsbanken Fonder AB and Handelsbanken Fonder AB. Company insiders that have sold Albemarle company stock in the last year include Douglas L Maine, Karen G Narwold, Luther C Iv Kissam, Matthew Juneau and Scott Tozier. View Insider Buying and Selling for Albemarle.

Which major investors are buying Albemarle stock?

ALB stock was acquired by a variety of institutional investors in the last quarter, including Carmignac Gestion, Iridian Asset Management LLC CT, Principal Financial Group Inc., Principal Financial Group Inc., BlackRock Inc., Artisan Partners Limited Partnership, Summit Trail Advisors LLC and Robecosam AG. View Insider Buying and Selling for Albemarle.

How do I buy shares of Albemarle?

Shares of ALB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albemarle's stock price today?

One share of ALB stock can currently be purchased for approximately $93.33.

How big of a company is Albemarle?

Albemarle has a market capitalization of $10.34 billion and generates $3.07 billion in revenue each year. The specialty chemicals company earns $54.85 million in net income (profit) each year or $4.59 on an earnings per share basis. Albemarle employs 5,400 workers across the globe.

How can I contact Albemarle?

Albemarle's mailing address is 4350 CONGRESS STREET SUITE 700, CHARLOTTE NC, 28209. The specialty chemicals company can be reached via phone at 980-299-5700.


MarketBeat Community Rating for Albemarle (ALB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  517 (Vote Outperform)
Underperform Votes:  398 (Vote Underperform)
Total Votes:  915
MarketBeat's community ratings are surveys of what our community members think about Albemarle and other stocks. Vote "Outperform" if you believe ALB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.